Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

ALX Oncology Holdings Inc. - Common Stock (NQ:ALXO)

1.105 -0.005 (-0.45%)
Streaming Delayed Price Updated: 3:15 PM EDT, Sep 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ALX Oncology Holdings Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
ALX Oncology to Participate in Upcoming Investor Conferences in September
From ALX Oncology
Via GlobeNewswire
Unusual volume stocks in Friday's session
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
Tuesday's pre-market session: top gainers and losers
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
ALX Oncology Holdings's Earnings: A Preview
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
From ALX Oncology
Via GlobeNewswire
What's Next: ALX Oncology Holdings's Earnings Preview
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
What's going on in today's session
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
ALX Oncology Holdings Inc (NASDAQ:ALXO) Reports Q2 2025 Results with Wider Loss but Strong Clinical Progress
ALX Oncology reports Q2 2025 results with a net loss of $25.9M, wider than expected, but shares dip only slightly. Clinical progress, including evorpacept data and ALX2004 trials, remains key focus.... 
Via Chartmill
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
From ALX Oncology
Via GlobeNewswire
Earnings Scheduled For August 12, 2025
 
Via Benzinga
Top movers in Tuesday's after hours session
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
From ALX Oncology
Via GlobeNewswire
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
From ALX Oncology
Via GlobeNewswire
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
Which stocks are moving on Thursday?
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Top movers in Thursday's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.